Caliway Pharma drug Cbl-514 shows statistically significant efficacy in Phase II trial
CALIWAY BIOPHARMACEUTICALS CO., LTD. announced on Sept. 21 that its new drug Cbl-514 demonstrated statistically significant efficacy in its Phase II clinical trial, meeting the primary efficacy endpoint.